People in Quebec living with Chronic Lymphocytic Leukemia (CLL) will now be able to access a new treatment option through the province’s prescription drug insurance plan.
Quebec becomes the first province to fund GAZYVA® for patients with CLL
Targeted treatment to be added to Quebec’s drug benefit formulary for patients with Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) patients in Quebec now have access to a new treatment option through the province’s prescribed drug insurance plan. On June 1, 2015, GAZYVA® (obinutuzumab) in combination with chlorambucil chemotherapy was added to Quebec’s Hospital Formulary. GAZYVA® was approved by Health Canada on November 25, 2014, in combination with chlorambucil, for the treatment of patients with previously untreated CLL.
GAZYVA®, a novel anti-CD20, combined with a mild chemotherapy works by directly targeting the patient’s disease and working with the body’s immune system to kill cancer cells.
“GAZYVA® is an important treatment option for the nearly 2,200 Canadians diagnosed with CLL each year. We are so pleased that the Quebec Minister of Health has decided to make this accessible to patients and Lymphoma Canada awaits the funding decisions in the other Canadian provinces. This is an exciting new era in the management of CLL”, says Lymphoma Canada CEO, Robin Markowitz.
Click here to read the full press release from the maufacturer.
